- Atai Life Sciences (NASDAQ:ATAI)-owned Perception Neuroscience announced that the Phase 2a trial of PCN-101 (R-ketamine) did not meet its primary endpoint of a statistically significant change from baseline in participants’ MADRS (Montgomery-Åsberg Depression Rating Scale) score at 24 hours compared to placebo.
- MADRS is a widely used clinicianâ€rated measure of depressive severity.
- The Phase 2a proof-of-concept trial was a two-week, randomized, double-blind, placebo-controlled multi-center study assessing the safety, tolerability, and efficacy of a single IV administration of PCN-101.
- 102 treatment-resistant depression (TRD) patients were enrolled across three arms – 30mg, 60mg, and placebo.
- On the primary endpoint of MADRS at 24 hours, the mean change from baseline was -15.3 for PCN-101 60mg compared to -13.7 for the placebo.
- However, the single 60mg dose of PCN-101 showed an efficacy signal at each time point over the 2-week timeframe of the study.
- Key secondary endpoints included a proportion of patients defined as responders. Despite the greater response and remission rates in the 60mg arm, the trial did not meet statistical significance on these secondary measures.
- PCN-101 was generally well-tolerated with rates of sedation and dissociation comparable to placebo.
- Atai will further evaluate the PCN-101 data in more detail over the next weeks and work to explore the next steps, including seeking strategic partnership options.
- Price Action: ATAI shares are down 40.3% at $1.56 on the last check Friday.
- Photo Via Company
Travere Therapeutics Announces Topline Results From Two-Year Primary Efficacy Endpoint In Pivotal Phase 3 DUPLEX Study Of Sparsentan In Focal Segmental Glomerulosclerosis; The Duplex Study Did Not Achieve The Primary Efficacy Endpoint Over 108 Weeks
The DUPLEX Study did not achieve the primary efficacy eGFR slope endpoint over 108 weeks of treatment
Secondary and topline exploratory endpoints trended favorably for sparsentan
Treatment with sparsentan resulted in a
